EUTECNIQAtlas

Every page of EUTECNIQ on one mapArrow keys move through results · Enter opens · Esc closes

Supplements A–Z Botanical Sources: 4

Echinacea Echinacea purpurea (L.) Moench

Also called: purple coneflower, coneflower, Echinacea angustifolia, Echinacea pallida

Echinacea species are perennials related to sunflowers and daisies, native east of the Rocky Mountains. E. purpurea, E. angustifolia and E. pallida extracts, from above-ground parts and roots, are most commonly used.

Category
Botanical
Part used
Above-ground parts and roots
Strongest evidence
C Limited
Reviewed
2026-10-28

Class 1 Well studied in people. A 2014 Cochrane review included 24 double-blind randomized trials (4,631 participants; 33 comparisons) of Echinacea mono-preparations versus placebo for colds. Preparations differed in species and plant part, and the main analysis was not pooled because of clinical heterogeneity. [3]

Fact-checked 2026-10-28 · How this guide is made

Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. EUTECNIQ sells no supplements today, and this page links to no product. Supplements can interact with medicines; ask a doctor or pharmacist before use, especially in pregnancy, while breastfeeding, before surgery or for a child.

Evidence

What research has studied

Grades describe the human evidence in the cited sources, not a recommendation. A means consistent randomized trials; X means good trials found no effect.

4 topics studied2 body areas · strongest grade C

A consistent trialsB some positive trialsC limited human evidenceD lab or animal onlyX no effect in good trials

From the table below Each topic in the table is placed on the part of the body it names, colored by its strongest grade. Tap an area, or open a line in the list, to see its topics. The map shows what was studied, not what Echinacea does: a C or X area is not evidence of benefit. All 1,071 findings on one body map.
Topics studied for Echinacea, evidence grade and finding
Topic studiedGradeWhat the evidence shows
Catching a cold (prevention trials)CCochrane (2014): none of 12 prevention comparisons was statistically significant; post hoc pooling suggested a 10% to 20% relative risk reduction of questionable clinical relevance. [3]
Duration of colds (treatment trials)COf seven treatment trials reporting cold duration, only one showed a significant effect; Cochrane authors said benefits were not shown but a weak benefit from some products is possible (24 trials, 4,631 participants). [3]
Respiratory infections in childrenCOne recent study suggested fewer infections, but NCCIH states overall evidence is insufficient to support a clear connection. [1]
Eczema and other conditionsCNCCIH states it is unclear whether echinacea helps other conditions, including eczema. [1]

Main constituents: Active ingredients not well defined; extracts contain polysaccharides, volatile oils, caffeic and ferulic acid derivatives, flavonoids, alkamides and polyenes [2]

Safety

Safety and side effects

  • Liver (NIH LiverTox)
    Score D
    A: well known causeE: unlikely cause

    LiverTox likelihood score D: possible rare cause of clinically apparent liver injury (chapter last updated April 10, 2019).

    Details and sources
  • Pregnancy and breastfeeding
    NCCIH: studies suggest echinacea is possibly safe for up to 7 days during the first trimester of pregnancy …

    1 statement in the profile.

    Details and sources
  • Interactions with medicines
    7 listed

    CYP1A2 and CYP3A4 substrates; Etoposide; Docetaxel; Digoxin (P-glycoprotein substrate); Immunosuppressants; Immunosuppressants; Caffeine

    Details and sources
  • Cancer evaluations (IARC, NTP)
    None found

    No IARC or NTP evaluation was found in the lists checked.

    Details and sources
  • FDA new dietary ingredient notifications
    None on FDA's list

    FDA does not approve dietary supplements. Each entry is one party's filing.

    Details and sources
  • Dose in official monographs
    Stated

    EU herbal monograph on Echinacea purpurea (L.) Moench, herba recens (EMA/HMPC/48704/2014 Corr 1, 24 November 2015), well-established use for the …

    Details and sources
  • Products with E. purpurea extracts, and some E. purpurea/E. angustifolia mixtures, are likely safe for most adults short term. Allergic reactions can occur and may be severe. [1]
  • Most common side effects are digestive: abdominal pain, nausea or stomach pain. [1]
  • Possibly safe for children short term, but some children in a trial developed rashes; consult the child's clinician. [1]
  • Possibly safe for up to 7 days in the first trimester of pregnancy; little is known about breastfeeding. [1]
  • LiverTox likelihood score D (possible rare cause of clinically apparent liver injury); not linked to liver injury in multiple controlled trials. [2]
Interactions

Interactions

Echinacea
From the table below 2 interactions the sources name. Tap one to read what happens. A line means a documented or possible interaction, not its size.
Known interactions of Echinacea
WithWhat happens
Drugs metabolized by the liverEchinacea-drug interactions have not been well defined; some preparations inhibit CYP1A2 and CYP3A4 in vitro and in vivo, with clinical significance not shown. [2]
Immunosuppressants and caffeineNCCIH notes theoretical reasons to suspect interactions. [1]

Tell a pharmacist or doctor about every supplement you take. All documented interactions in this hub.

Quality

Identity, quality and standardization

  • Products sold as echinacea differ appreciably in composition because of variable plant material, extraction methods and added components. [3]
  • NCCIH-sponsored research suggests extract activity is influenced by soil conditions that affect the plant's bacterial community. [1]
Regulation

Regulatory status

  • US: herbal products for oral use are often marketed as dietary supplements, which, unlike drugs, are not approved by the FDA before sale; manufacturers are responsible for safety and labeling. [1]
  • EU: an EU herbal monograph covers well-established short-term oral use of purple coneflower herb for common colds in adults and adolescents over 12, and traditional use for superficial wounds. [4]
Profile

Safety, quality and supply profile

Fourteen questions a careful buyer, formulator or clinician would ask, each answered only from a cited source (checked 2026-10-29). If our sources do not answer a question, we say so.

Compounds responsible

Compounds the sources name as the main or characteristic actives.

  • Cichoric and caftaric acids Phenolic acids and simple phenols (caffeic acid derivatives) [P9]
  • Alkylamides (alkamides), e.g. dodeca-2E,4E,8Z,10E/Z-tetraenoic acid isobutylamides Fatty acids and lipids (fatty acid amides) [P10]
  • Polysaccharides (LiverTox: active ingredients not well defined; extracts contain multiple polysaccharides) Polysaccharides [P8]

US status

What FDA's published records show. FDA does not approve dietary supplements.

  • No NDI notification naming echinacea (Echinacea species) was found in FDA's published NDI list (dated July 9, 2026; checked 2026-10-29). FDA keeps no authoritative list of ingredients marketed before October 15, 1994. [P1]

Cancer evaluations (IARC and NTP)

Evaluations name the exact material tested, which may differ from a supplement.

  • No IARC or NTP carcinogenicity evaluation of echinacea was found (IARC Monographs list of classifications and NTP technical reports checked 2026-10-29). [P2]
  • The NTP Technical Reports index (TR-001 to TR-606) lists no 2-year study of echinacea (checked 2026-10-29). [P3]

Liver (NIH LiverTox)

  • LiverTox likelihood score D: possible rare cause of clinically apparent liver injury (chapter last updated April 10, 2019). [P8]

Interactions with medicines

  • CYP1A2 and CYP3A4 substrates: LiverTox: echinacea-drug interactions have not been well defined; some preparations interfere with CYP1A2 and 3A4 activity in vitro and in vivo, but the clinical significance of these interactions has not been shown. [P8]
  • Etoposide: Profound thrombocytopenia in a patient receiving etoposide, likely due to CYP3A4 inhibition (case report). [P9]
  • Docetaxel: In cancer patients receiving docetaxel, echinacea did not significantly alter docetaxel pharmacokinetics. [P9]
  • Digoxin (P-glycoprotein substrate): Echinacea inhibited P-gp in vitro, but supplementation in humans did not affect digoxin pharmacokinetics. [P9]
  • Immunosuppressants: NCCIH notes theoretical reasons to suspect an interaction. [P7]
  • Immunosuppressants: MSK: echinacea may antagonize the effects of immunosuppressants; clinical relevance is not known. [P9]
  • Caffeine: NCCIH notes theoretical reasons to suspect an interaction. [P7]

Alcohol

  • No published information found in the sources checked.

Interactions with other herbs and supplements

  • No published information found in the sources checked.

Adulteration and substitution

  • A review of 78 publications estimated that 28.5% of echinacea root or herb samples (n = 200) were adulterated and/or mislabeled; products sold as licensed or registered herbal medicines had a lower risk than dietary or food supplements. [P5]
  • In 53 echinacea products sold in Europe, DNA metabarcoding detected Echinacea in 34 of 38 retained products but could not resolve species; overall ingredient fidelity versus labels was 43% (Raclariu et al., 2018). [P11]

What a certificate of analysis should cover

Tests a quality specification for this material would include, with the reason for each.

  • Identity: at least one appropriate test or examination to verify the identity of each component that is a dietary ingredient (21 CFR 111.75(a)(1)(i)) — General Part 111 requirement for every dietary ingredient; FDA may exempt a firm only by granting a petition under 111.75(a)(1)(ii). [P4]
  • HPTLC for Echinacea marker compounds combined with DNA metabarcoding for other plant species — HPTLC resolves Echinacea target compounds but does not reveal other species; metabarcoding detected unlabeled species in tested products. [P11]

Supply and conservation

  • Echinacea purpurea: IUCN Red List: Least Concern (LC), via GBIF species API, retrieved 2026-10-29 [P6]
  • Though widely cultivated today, echinacea species are native to areas east of the Rocky Mountains in the United States. [P7]

Absorption in people

  • After single doses of three E. purpurea preparations in humans, maximum plasma concentrations of the main tetraenoic acid isobutylamides were 0.22–0.23 ng/mL, with AUCs of 0.20–0.23 ng/mL·h. [P10]

Formulations studied to change absorption

Human data only.

  • No published information found in the sources checked.

Dose in official monographs

As the monograph states it, for its jurisdiction; not personal advice.

  • EU herbal monograph on Echinacea purpurea (L.) Moench, herba recens (EMA/HMPC/48704/2014 Corr 1, 24 November 2015), well-established use for the common cold, adolescents 12 years and older and adults: expressed juice 1.5–4.5 mL per dose, 6–9 mL daily, for no more than 10 days. [P12]

Pregnancy and breastfeeding

  • NCCIH: studies suggest echinacea is possibly safe for up to 7 days during the first trimester of pregnancy; little is known about use while breastfeeding. [P7]

Sources for this profile

  1. FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
  2. IARC Monographs. List of Classifications: agents classified by the IARC Monographs, Volumes 1–142 (last updated 2026-07-23), 2026-07-23. monographs.iarc.who.int
  3. National Toxicology Program. Technical Reports (TR series index, TR-001 to TR-606), 2026-10-29. ntp.niehs.nih.gov
  4. eCFR. 21 CFR 111.75, What must you do to determine whether specifications are met? (up to date as of 10/23/2026), 2026-10-23. ecfr.gov
  5. Orhan N, Gafner S, Blumenthal M. Estimating the extent of adulteration of the popular herbs black cohosh, echinacea, elder berry, ginkgo, and turmeric: its challenges and limitations. Nat Prod Rep 2024;41(10):1604-1621 (PMID 39108221), 2024-10-17. pubmed.ncbi.nlm.nih.gov
  6. GBIF species API: IUCN Red List category for Echinacea purpurea, 2026-10-29. api.gbif.org
  7. NCCIH. Echinacea: Usefulness and Safety (Last Updated: November 2024), 2024-11. nccih.nih.gov
  8. NIH LiverTox (NIDDK). Echinacea (Last Update: April 10, 2019), 2019-04-10. ncbi.nlm.nih.gov
  9. Memorial Sloan Kettering Cancer Center. About Herbs: Echinacea (last updated August 7, 2023), 2023-08-07. mskcc.org
  10. Woelkart K, et al. Pharmacokinetics of the main alkamides after administration of three different Echinacea purpurea preparations in humans. Planta Med 2008;74(6):651-656 (PMID 18240099), 2008-05. pubmed.ncbi.nlm.nih.gov
  11. Raclariu AC, et al. What's in the box? Authentication of Echinacea herbal products using DNA metabarcoding and HPTLC. Phytomedicine 2018;44:32-38 (PMID 29895490), 2018-05-15. pubmed.ncbi.nlm.nih.gov
  12. European Medicines Agency, HMPC. European Union herbal monograph on Echinacea purpurea (L.) Moench, herba recens, EMA/HMPC/48704/2014 Corr 1 (24 November 2015), 2015-11-24. ema.europa.eu
Sources

Sources

  1. NCCIH. Echinacea: Usefulness and Safety (Last Updated: 2024-11), 2024-11. nccih.nih.gov
  2. NIH LiverTox (NIDDK). Echinacea (Last Update: 2019-04-10), 2019-04-10. ncbi.nlm.nih.gov
  3. Cochrane Database of Systematic Reviews. Karsch-Völk M, Barrett B, Kiefer D, et al. Echinacea for preventing and treating the common cold. 2014;(2):CD000530 (PubMed abstract, PMID 24554461), 2014-02-20. pubmed.ncbi.nlm.nih.gov
  4. European Medicines Agency, HMPC. Echinaceae purpureae herba (purple coneflower herb) - herbal medicinal product, 2016-02-17. ema.europa.eu
A
Consistent results from several randomized trials or a systematic review of them
B
Some positive randomized trials, but small, short, few or inconsistent
C
Limited human evidence: single small trials, observational data or mixed results
D
Laboratory or animal evidence only; not shown in people
X
Well-designed human trials found no meaningful effect

More in botanical: Aloe vera · American ginseng · Amla · Andrographis · Arjuna · Arnica · Aronia (black chokeberry) · Asafoetida · All entries A–Z · How to judge a supplement

Health information notice

These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.

Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.

EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.

Ready to check what you take?

Free tools built on published reference values, each with its sources and its limits. Your lists stay in your browser.